Stinchcombe TE - Search Results

1

Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).

Wong ML, Gao J, Thanarajasingam G, Sloan JA, Dueck AC, Novotny PJ, Jatoi A, Hurria A, Walter LC, Miaskowski C, Cohen HJ, Wood WA, Feliciano JL, Stinchcombe TE, Wang X. Wong ML, et al. Among authors: stinchcombe te. Oncologist. 2021 Mar;26(3):e435-e444. doi: 10.1002/onco.13527. Epub 2020 Oct 1. Oncologist. 2021. PMID: 32951293 Free PMC article.

2

Drug development in patients with advanced non-small cell lung cancer and poor performance status.

Stinchcombe TE, Socinski MA. Stinchcombe TE, et al. Semin Oncol. 2004 Dec;31(6 Suppl 11):21-6. doi: 10.1053/j.seminoncol.2004.10.005. Semin Oncol. 2004. PMID: 15599831 Review.

3

The evolving role of pemetrexed (Alimta) in lung cancer.

Socinski MA, Stinchcombe TE, Hayes DN. Socinski MA, et al. Among authors: stinchcombe te. Semin Oncol. 2005 Apr;32(2 Suppl 2):S16-22. doi: 10.1053/j.seminoncol.2005.02.008. Semin Oncol. 2005. PMID: 15818533 Review.

4

Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status.

Stinchcombe TE, Choi J, Schell MJ, Mears A, Jones PE, Nachtsheim RV, Socinski MA. Stinchcombe TE, et al. Lung Cancer. 2006 Feb;51(2):237-43. doi: 10.1016/j.lungcan.2005.10.018. Epub 2005 Dec 27. Lung Cancer. 2006. PMID: 16378657 Clinical Trial.

5

The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy.

Socinski MA, Stinchcombe TE, Hayes DN, Morris DE. Socinski MA, et al. Among authors: stinchcombe te. Semin Oncol. 2006 Feb;33(1 Suppl 1):S32-8. doi: 10.1053/j.seminoncol.2005.12.006. Semin Oncol. 2006. PMID: 16472707 Review.

6

Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.

Stinchcombe TE, Morris DE, Moore DT, Bechtel JH, Halle JS, Mears A, Deschesne K, Rosenman JG, Socinski MA. Stinchcombe TE, et al. Lung Cancer. 2006 Apr;52(1):67-74. doi: 10.1016/j.lungcan.2005.11.008. Epub 2006 Feb 24. Lung Cancer. 2006. PMID: 16499996

7

A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.

Stinchcombe TE, Bůzková P, Choksi J, Taylor M, Bakri K, Gillenwater H, Tynan M, Mears A, Jones PE, Socinski MA. Stinchcombe TE, et al. Lung Cancer. 2006 Jun;52(3):305-11. doi: 10.1016/j.lungcan.2006.03.002. Epub 2006 Apr 25. Lung Cancer. 2006. PMID: 16638621 Clinical Trial.

8

Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status.

Stinchcombe TE, Lee CB, Socinski MA. Stinchcombe TE, et al. Clin Lung Cancer. 2006 May;7 Suppl 4:S111-7. doi: 10.3816/clc.2006.s.002. Clin Lung Cancer. 2006. PMID: 16764751 Review.

9

Combined modality therapy for stage III non-small cell lung cancer.

Stinchcombe TE, Fried D, Morris DE, Socinski MA. Stinchcombe TE, et al. Oncologist. 2006 Jul-Aug;11(7):809-23. doi: 10.1634/theoncologist.11-7-809. Oncologist. 2006. PMID: 16880240 Free article. Review.

10

Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.

Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Lee CB, et al. Among authors: stinchcombe te. Clin Lung Cancer. 2006 Nov;8(3):195-202. doi: 10.3816/CLC.2006.n.047. Clin Lung Cancer. 2006. PMID: 17239295 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

186 results

Search Page